Compare IPSC & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPSC | EBS |
|---|---|---|
| Founded | 2019 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 425.9M | 411.1M |
| IPO Year | 2021 | 2006 |
| Metric | IPSC | EBS |
|---|---|---|
| Price | $2.22 | $8.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $4.25 | ★ $12.00 |
| AVG Volume (30 Days) | ★ 1.2M | 638.8K |
| Earning Date | 05-14-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 91.30 | ★ 125.83 |
| EPS | N/A | ★ 0.93 |
| Revenue | $109,164,000.00 | ★ $742,900,000.00 |
| Revenue This Year | N/A | $1.29 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $8.66 |
| Revenue Growth | ★ 1556.76 | N/A |
| 52 Week Low | $0.44 | $4.71 |
| 52 Week High | $2.97 | $14.06 |
| Indicator | IPSC | EBS |
|---|---|---|
| Relative Strength Index (RSI) | 46.99 | 43.26 |
| Support Level | $1.87 | $7.73 |
| Resistance Level | $2.67 | $8.54 |
| Average True Range (ATR) | 0.17 | 0.34 |
| MACD | -0.01 | 0.02 |
| Stochastic Oscillator | 28.45 | 21.09 |
Century Therapeutics Inc is a biotechnology company harnessing the power of allogeneic pluripotent stem cell therapies to develop potentially curative cell therapy products for autoimmune diseases, including type 1 diabetes, or T1D, and cancer. Its beta islet, T cell and NK cell programs are allogeneic, meaning it is derived from healthy donors for use in any patient, rather than being sourced from an individual for their own specific use, as is the case with autologous T cells. The cell types it can generate from iPSCs, including iPSC-derived beta islet cells, iPSC-derived CD4+ and CD8+ alphabeta T cells, or alphabeta iT cells, and iPSC- natural killer cells, or iNK cells.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. Geographically, the company operates in United States, Canada, and Others. It derives maximum revenue from United states. The company's products include: NARCAN Nasal Spray, KLOXXADO Nasal Spray, ACAM2000, ANTHRASIL, BAT, BioThrax, CNJ-016, raxibacumab injection, Ebanga, and others.